Authors: Loriot, Yohann, Necchi, Andrea, Park, Se Hoon, Garcia-Donas, Jesus, Huddart, Robert, Burgess, Earle, Fleming, Mark, Rezazadeh, Arash, Mellado, Begoña, Varlamov, Sergey, Joshi, Monika, Duran, Ignacio, Tagawa, Scott, Zakharia, Yousef, Zhong, Bob, Stuyckens, Kim, Santiago-Walker, Ademi, De Porre, Peter, O’Hagan, Anne, Avadhani, Anjali, Siefker-Radtke, Arlene, Houédé, Nadine
Contributors: Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Fondazione IRCCS Istituto Nazionale dei Tumori, Samsung Medical Center Sungkyunkwan University School of Medicine, Institute Division of Hematology/Oncology, Centro Integral Oncologico Clara Campal, Academic Radiotherapy Unit, Institute of cancer research, The Levine Cancer Institute, Virginia Oncology Associates, University of Louisville, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Scientific Information Analyses, Siberian Research Institute of Cheese-Making, Barnaul, Russia, Department of Veterinary and Biomedical Sciences, Penn State Cancer Institute, The Pennsylvania State University, 115 Henning Building, University Park, PA 16802, USA., Marqués de Valdecilla University Hospital [Santander], Weill Medical College of Cornell University [New York], Department of Pediatrics and Holden Comprehensive Cancer Center [Iowa City, USA], University of Iowa [Iowa City]-Carver College of Medicine, University of Iowa, Janssen Research & Development [Spring House, PA, USA], Janssen Pharmaceutica [Beerse], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Loriot, Y, Necchi, A, Park, Sh, Garcia-Donas, J, Huddart, R, Burgess, E, Fleming, M, Rezazadeh, A, Mellado, B, Varlamov, S, Joshi, M, Duran, I, Tagawa, St, Zakharia, Y, Zhong, B, Stuyckens, K, Santiago-Walker, A, De Porre, P, O'Hagan, A, Avadhani, A, Siefker-Radtke, Ao
Source:
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2019, 381 (4), pp.338-348. ⟨10.1056/NEJMoa1817323⟩
Subject Terms: MESH: Antineoplastic Agents / administration & dosage, Kaplan-Meier Estimate, Protein Kinase Inhibitors / administration & dosage, Pyrazoles / administration & dosage, MESH: Quinoxalines / administration & dosage, Receptors, Fibroblast Growth Factor / antagonists & inhibitors, Receptors, Fibroblast Growth Factor / genetics, Urologic Neoplasms / drug therapy, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, General Medicine, Receptor, Metastatic Urothelial Carcinoma, Cancer research, Erdafitinib, Mutation, medicine.disease_cause, medicine, Immune system, Urothelium, business.industry, business, Progression-free survival, Fibroblast growth factor receptor
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffcfc170e758d7ea02e09dd18fd05524
https://hal.archives-ouvertes.fr/hal-02930806
Authors: Hakan Goker, Emre Tekgündüz, Erman Öztürk, Fevzi Altuntaş, Sinem Civriz Bozdag, Evren Ozdemir, Yahya Buyukasik, Ismail Sari, Ayşegül Tetik, Leylagül Kaynar, Serdal Korkmaz, Cigdem Pala, Sibel Hacioglu, Mehmet Hilmi Dogu, Burhan Turgut
Contributors: [Tekgunduz, Emre -- Tetik, Aysegul -- Bozdag, Sinem Civriz -- Altuntas, Fevzi] Ankara Oncol Training & Res Hosp, Hematol & Stem Cell Transplantat Clin, TR-06200 Ankara, Turkey -- [Goker, Hakan -- Buyukasik, Yahya] Hacettepe Univ, Sch Med, Dept Internal Med, Div Hematol, Ankara, Turkey -- [Kaynar, Leylagul -- Pala, Cigdem] Erciyes Univ, Sch Med, Dept Internal Med, Div Hematol, Kayseri, Turkey -- [Sari, Ismail -- Dogu, Mehmet Hilmi -- Hacioglu, Sibel Kabukcu] Pamukkale Univ, Sch Med, Dept Internal Med, Div Hematol, Denizli, Turkey -- [Ozturk, Erman] Koc Univ, Sch Med, Dept Internal Med, Div Hematol, Istanbul, Turkey -- [Turgut, Burhan] Namik Kemal Univ, Sch Med, Dept Internal Med, Div Hematol, Tekirdag, Turkey -- [Korkmaz, Serdal] Cumhuriyet Univ, Sch Med, Dept Internal Med, Div Hematol, Sivas, Turkey -- [Ozdemir, Evren] Hacettepe Univ, Sch Med, Dept Internal Med, Div Oncol, Ankara, Turkey, Kaynar, Leylagul -- 0000-0002-2035-9462, Bayram, Cem -- 0000-0001-8717-4668, Kaynar, leylagul -- 0000-0002-2035-9462, Altuntas, Fevzi -- 0000-0001-6872-3780
Subject Terms: Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Combined Modality Therapy/adverse effects/methods, Disease Management, Female, Hematopoietic Stem Cell Transplantation/adverse effects/methods, Humans, Male, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis/mortality/*therapy, Protein Kinase Inhibitors/administration & dosage/therapeutic use, Retrospective Studies, Survival Analysis, Treatment Outcome, Young Adult, respiratory tract diseases, hemic and lymphatic diseases, humanities, Cancer Research, Oncology, Hematology, Cohort, Philadelphia Chromosome Positive, Chemotherapy, medicine.medical_treatment, medicine, Internal medicine, medicine.medical_specialty, Surgery, Daily practice, Gastroenterology, Population study, Philadelphia chromosome, medicine.disease, business.industry, business, Lymphoblastic Leukemia, Transplantation, Acute lymphoblastic leukemia, Allogeneic transplantation, BCR-ABL, Stem cell transplantation, antineoplastic agent, cyclosporin, dasatinib, imatinib, methotrexate, protein kinase inhibitor, adult, aged, allotransplantation, Article, cancer chemotherapy, cancer patient, cancer survival, clinical article, cohort analysis, female, graft versus host reaction, hematopoietic cell, human, leukemia remission, male, medical practice, overall survival, Philadelphia chromosome positive cell, retrospective study, treatment response, adverse effects, clinical trial, disease management, hematopoietic stem cell transplantation, middle aged, mortality, multicenter study, multimodality cancer therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma, procedures, survival analysis, treatment outcome, young adult, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Protein Kinase Inhibitors
Access URL: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::523e1e7ed3934c8d7991cf8c6b6902cf
Authors: Chalandon, Yves, Thomas, Xavier, Hayette, Sandrine, Cayuela, Jean-Michel, Abbal, Claire, Huguet, Françoise, Raffoux, Emmanuel, Leguay, Thibaut, Rousselot, Philippe, Lepretre, Stéphane, Escoffre-Barbe, Martine, Maury, Sébastien, Berthon, Céline, Tavernier, Emmanuelle, Lambert, Jean-François, Lafage-Pochitaloff, Marina, Lhéritier, Véronique, Chevret, Sylvie, Ifrah, Norbert, Dombret, Hervé, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
Source: Blood, Vol. 125, No 24 (2015) pp. 3711-3719
Subject Terms: ddc:616, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Antineoplastic Combined Chemotherapy Protocols / therapeutic use, Antineoplastic Combined Chemotherapy Protocols / toxicity, Benzamides / administration & dosage, Benzamides / therapeutic use, Benzamides / toxicity, Disease-Free Survival, Female, Humans, Imatinib Mesylate, Male, Middle Aged, Philadelphia Chromosome, Piperazines / administration & dosage, Piperazines / therapeutic use, Piperazines / toxicity, Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy, Protein Kinase Inhibitors / administration & dosage, Protein Kinase Inhibitors / therapeutic use, Protein Kinase Inhibitors / toxicity, Pyrimidines / administration & dosage, Pyrimidines / therapeutic use, Pyrimidines / toxicity, Stem Cell Transplantation, Treatment Outcome, Young Adult, hemic and lymphatic diseases, Cell Biology, Hematology, Immunology, Biochemistry, Acute lymphocytic leukemia, medicine.disease, medicine, Regimen, Gastroenterology, medicine.medical_specialty, Vincristine, medicine.drug, Internal medicine, business.industry, business, Chemotherapy, medicine.medical_treatment, Cyclophosphamide, Surgery, Imatinib mesylate, Imatinib, Transplantation
Access URL:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76ff7b8fa7c747ce8aaa642d7f259a20
https://archive-ouverte.unige.ch/unige:158640
Source: Ascierto , P A , Ferrucci , P F , Fisher , R , Del Vecchio , M , Atkinson , V , Schmidt , H , Schachter , J , Queirolo , P , Long , G V , Di Giacomo , A M , Svane , I M , Lotem , M , Bar-Sela , G , Couture , F , Mookerjee , B , Ghori , R , Ibrahim , N , Moreno , B H & Ribas , A 2019 , ' Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma ' , Nature Medicine , vol. 25 , no. 6 , pp. 941-946 .
Index Terms: Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/administration & dosage, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Double-Blind Method, Female, Humans, Imidazoles/administration & dosage, Kaplan-Meier Estimate, MAP Kinase Kinase Kinases/antagonists & inhibitors, Male, Melanoma/drug therapy, Middle Aged, Mutation, Oximes/administration & dosage, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors/administration & dosage, Proto-Oncogene Proteins B-raf/antagonists & inhibitors, Pyridones/administration & dosage, Pyrimidinones/administration & dosage, Skin Neoplasms/drug therapy, Young Adult, article
URL:
Source: Hasselbalch , H C & Holmström , M O 2019 , ' Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms : minimal residual disease and cure? ' , Seminars in Immunopathology , vol. 41 , no. 1 , pp. 5-19 .
Index Terms: Disease Progression, Humans, Immunologic Surveillance, Inflammation/diagnosis, Interferon-alpha/administration & dosage, Mutation, Myeloproliferative Disorders/diagnosis, Neoplasm, Residual, Polycythemia Vera/diagnosis, Protein Kinase Inhibitors/administration & dosage, Treatment Outcome, article
URL:
Source: Hasselbalch , H C & Holmström , M O 2019 , ' Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms : minimal residual disease and cure? ' , Seminars in Immunopathology , vol. 41 , no. 1 , pp. 5-19 .
Index Terms: Disease Progression, Humans, Immunologic Surveillance, Inflammation/diagnosis, Interferon-alpha/administration & dosage, Mutation, Myeloproliferative Disorders/diagnosis, Neoplasm, Residual, Polycythemia Vera/diagnosis, Protein Kinase Inhibitors/administration & dosage, Treatment Outcome, article
URL:
Source: Ahn , I E , Farooqui , M Z H , Tian , X , Valdez , J , Sun , C , Soto , S , Lotter , J , Housel , S , Stetler-Stevenson , M , Yuan , C M , Maric , I , Calvo , K R , Nierman , P , Hughes , T E , Saba , N S , Marti , G E , Pittaluga , S , Herman , S E M , Niemann , C U , Pedersen , L B , Geisler , C H , Childs , R , Aue , G & Wiestner , A 2018 , ' Depth and durability of response to ibrutinib in CLL : 5-year follow-up of a phase 2 study ' , Blood , vol. 131 , no. 21 , pp. 2357-2366 .
Index Terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents/administration & dosage, Bone Marrow/metabolism, Female, Follow-Up Studies, Humans, Kaplan-Meier Estimate, Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis, Male, Middle Aged, Neoplasm Staging, Neoplasm, Residual, Protein Kinase Inhibitors/administration & dosage, Pyrazoles/administration & dosage, Pyrimidines/administration & dosage, Treatment Outcome, article
URL:
Source: Knapper , S , Russell , N , Gilkes , A , Hills , R K , Gale , R E , Cavenagh , J D , Jones , G , Kjeldsen , L , Grunwald , M R , Thomas , I , Konig , H , Levis , M J & Burnett , A K 2017 , ' A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML ' , Blood , vol. 129 , no. 9 , pp. 1143-1154 .
Index Terms: Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carbazoles/administration & dosage, Child, Child, Preschool, Consolidation Chemotherapy, Disease-Free Survival, Female, Hematopoietic Stem Cell Transplantation/methods, Humans, Induction Chemotherapy, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute/drug therapy, Male, Middle Aged, Mutation, Proportional Hazards Models, Protein Kinase Inhibitors/administration & dosage, Young Adult, fms-Like Tyrosine Kinase 3/antagonists & inhibitors, article
URL:
Source: International journal of oncology, 43 (3
Index Terms: Cancérologie, Médecine pathologie humaine, Sciences bio-médicales et agricoles, Cell Line, Tumor, Gene Expression Regulation, Neoplastic -- drug effects, Humans, Janus Kinases -- antagonists & inhibitors, MAP Kinase Kinase Kinases -- antagonists & inhibitors, Melanoma -- drug therapy -- genetics -- pathology, Molecular Targeted Therapy, Phosphatidylinositol 3-Kinases -- antagonists & inhibitors, Protein Kinase Inhibitors -- administration & dosage, Signal Transduction -- drug effects -- genetics, Transcriptome -- drug effects, src-Family Kinases -- antagonists & inhibitors, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: British Journal of Cancer, 107 (10
Index Terms: Sciences bio-médicales et agricoles, Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use, Bone Density Conservation Agents -- administration & dosage -- adverse effects, Bone Neoplasms -- drug therapy -- pathology -- secondary, Carcinoma, Renal Cell -- drug therapy -- pathology -- secondary, Diphosphonates -- administration & dosage -- adverse effects, Disease-Free Survival, Female, Humans, Indoles -- administration & dosage, Kidney Neoplasms -- drug therapy -- pathology, Male, Middle Aged, Neoplasm Metastasis, Niacinamide -- administration & dosage -- analogs & derivatives, Osteonecrosis -- chemically induced, Phenylurea Compounds -- administration & dosage, Prognosis, Protein Kinase Inhibitors -- administration & dosage, Protein-Tyrosine Kinases -- antagonists & inhibitors, Pyrroles -- administration & dosage, Retrospective Studies, Treatment Outcome, Bisphosphonates, Bone metastases, Osteonecrosis of the jaw, Outcome, Renal cell carcinoma, Targeted therapy, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: British Journal of Cancer, 107 (10
Index Terms: Sciences bio-médicales et agricoles, Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use, Bone Density Conservation Agents -- administration & dosage -- adverse effects, Bone Neoplasms -- drug therapy -- pathology -- secondary, Carcinoma, Renal Cell -- drug therapy -- pathology -- secondary, Diphosphonates -- administration & dosage -- adverse effects, Disease-Free Survival, Female, Humans, Indoles -- administration & dosage, Kidney Neoplasms -- drug therapy -- pathology, Male, Middle Aged, Neoplasm Metastasis, Niacinamide -- administration & dosage -- analogs & derivatives, Osteonecrosis -- chemically induced, Phenylurea Compounds -- administration & dosage, Prognosis, Protein Kinase Inhibitors -- administration & dosage, Protein-Tyrosine Kinases -- antagonists & inhibitors, Pyrroles -- administration & dosage, Retrospective Studies, Treatment Outcome, Bisphosphonates, Bone metastases, Osteonecrosis of the jaw, Outcome, Renal cell carcinoma, Targeted therapy, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Journal of clinical pharmacology, 51 (12
Index Terms: Cancérologie, Adult, Aged, Antineoplastic Agents -- administration & dosage, Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- blood -- pharmacokinetics, Area Under Curve, Benzenesulfonates -- administration & dosage, Colonic Neoplasms -- drug therapy -- metabolism, Deoxycytidine -- administration & dosage -- analogs & derivatives, Diarrhea -- chemically induced, Fatigue -- chemically induced, Female, Fluorouracil -- administration & dosage -- analogs & derivatives, Hand-Foot Syndrome -- etiology, Humans, Male, Middle Aged, Neoplasms -- drug therapy -- metabolism, Protein Kinase Inhibitors -- administration & dosage, Pyridines -- administration & dosage, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Current opinion in oncology, 23 (6
Index Terms: Cancérologie, Animals, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Breast Neoplasms -- drug therapy -- enzymology, Female, Humans, Mammary Neoplasms, Experimental -- drug therapy -- enzymology, Molecular Targeted Therapy, Protein Kinase Inhibitors -- administration & dosage, Receptor, erbB-2 -- antagonists & inhibitors -- biosynthesis, breast cancer, human epidermal growth factor 2 (HER2), neoadjuvant, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Journal of clinical pharmacology, 51 (12
Index Terms: Cancérologie, Adult, Aged, Antineoplastic Agents -- administration & dosage, Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- blood -- pharmacokinetics, Area Under Curve, Benzenesulfonates -- administration & dosage, Colonic Neoplasms -- drug therapy -- metabolism, Deoxycytidine -- administration & dosage -- analogs & derivatives, Diarrhea -- chemically induced, Fatigue -- chemically induced, Female, Fluorouracil -- administration & dosage -- analogs & derivatives, Hand-Foot Syndrome -- etiology, Humans, Male, Middle Aged, Neoplasms -- drug therapy -- metabolism, Protein Kinase Inhibitors -- administration & dosage, Pyridines -- administration & dosage, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Current opinion in oncology, 23 (6
Index Terms: Cancérologie, Animals, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Breast Neoplasms -- drug therapy -- enzymology, Female, Humans, Mammary Neoplasms, Experimental -- drug therapy -- enzymology, Molecular Targeted Therapy, Protein Kinase Inhibitors -- administration & dosage, Receptor, erbB-2 -- antagonists & inhibitors -- biosynthesis, breast cancer, human epidermal growth factor 2 (HER2), neoadjuvant, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Lancet, 377
Index Terms: Sciences bio-médicales et agricoles, Angiogenesis Inhibitors -- administration & dosage, Antibodies, Monoclonal -- administration & dosage, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Carcinoma, Non-Small-Cell Lung -- drug therapy -- mortality, Disease-Free Survival, Double-Blind Method, Humans, Lung Neoplasms -- drug therapy -- mortality, Protein Kinase Inhibitors -- administration & dosage, Quinazolines -- administration & dosage, Receptor, Epidermal Growth Factor -- antagonists & inhibitors, Salvage Therapy, Survival Rate, Vascular Endothelial Growth Factor A -- antagonists & inhibitors, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: The New England journal of medicine, 362 (24
Index Terms: Cancérologie, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents -- administration & dosage -- adverse effects -- therapeutic use, Blast Crisis -- prevention & control, Disease Progression, Female, Fusion Proteins, bcr-abl -- antagonists & inhibitors, Humans, Kaplan-Meier Estimate, Leukemia, Myeloid, Chronic-Phase -- drug therapy -- pathology, Male, Middle Aged, Piperazines -- adverse effects -- therapeutic use, Protein Kinase Inhibitors -- administration & dosage -- adverse effects -- therapeutic use, Pyrimidines -- administration & dosage -- adverse effects -- therapeutic use, Young Adult, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Oncology Reports, 22 (1
Index Terms: Anatomopathologie, Médecine pathologie humaine, Angiogenesis Inhibitors -- administration & dosage, Animals, Antigens, CD95 -- metabolism, Antimetabolites, Antineoplastic -- administration & dosage, Antineoplastic Combined Chemotherapy Protocols -- pharmacology, Apoptosis -- drug effects, Caspase 3 -- metabolism, Cell Line, Tumor, Chemotherapy, Adjuvant, Deoxycytidine -- administration & dosage -- analogs & derivatives, Epidermal Growth Factor -- metabolism, Indoles -- administration & dosage, Male, Mice, Microvessels -- drug effects, Neovascularization, Pathologic -- drug therapy -- enzymology -- pathology, Pancreatic Neoplasms -- blood supply -- drug therapy -- enzymology -- pathology -- radiotherapy, Pregnancy Proteins -- metabolism, Protein Kinase Inhibitors -- administration & dosage, Pyrroles -- administration & dosage, Radiotherapy, Adjuvant, Time Factors, Vascular Endothelial Growth Factor A -- metabolism, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Cancer research, 69 (11
Index Terms: Sciences bio-médicales et agricoles, Benzamides -- administration & dosage, Benzamides -- pharmacology, Cell Line, Tumor, Cell Proliferation -- drug effects, Cyclin-Dependent Kinase 4 -- metabolism, DNA Replication -- drug effects, Drug Combinations, Drug Evaluation, Preclinical, Glioblastoma -- metabolism, Glioblastoma -- pathology, Humans, MAP Kinase Kinase 1 -- antagonists & inhibitors, MAP Kinase Kinase 2 -- antagonists & inhibitors, Phosphorylation -- drug effects, Protein Kinase Inhibitors -- administration & dosage, Protein Kinase Inhibitors -- pharmacology, Protein Kinases -- metabolism, Proteins -- antagonists & inhibitors, Proteins -- metabolism, Retinoblastoma Protein -- metabolism, Sirolimus -- administration & dosage, Sirolimus -- pharmacology, Transcription Factors -- antagonists & inhibitors, Tumor Cells, Cultured, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL:
Source: Targeted oncology, 4 (2
Index Terms: Sciences bio-médicales et agricoles, Adjuvants, Immunologic -- administration & dosage, Anthracyclines -- administration & dosage, Antibodies, Monoclonal -- administration & dosage, Antibodies, Monoclonal -- adverse effects, Breast Neoplasms -- immunology, Breast Neoplasms -- mortality, Breast Neoplasms -- pathology, Breast Neoplasms -- physiopathology, Breast Neoplasms -- therapy, Drug Resistance, Neoplasm, Female, Heart Failure -- chemically induced, Humans, Oxidative Stress, Protein Kinase Inhibitors -- administration & dosage, Protein Kinase Inhibitors -- adverse effects, Quinazolines -- administration & dosage, Quinazolines -- adverse effects, Receptor, Epidermal Growth Factor -- antagonists & inhibitors, Receptor, erbB-2 -- antagonists & inhibitors, Receptor, erbB-2 -- immunology, Survival Rate, Ventricular Outflow Obstruction -- chemically induced, Anti-HER-2 therapies, Breast cancer, Cardiotoxicity, Lapatinib, Trastuzumab, info:eu-repo/semantics/article, info:ulb-repo/semantics/articlePeerReview, info:ulb-repo/semantics/openurl/article
URL: